Reading SOLV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SOLV free→Reading SOLV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SOLV free→QuarterlyIQ Insights · SOLV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On May 10, 2024, Plaintiff Eric Gilbert (the “Plaintiff”), on behalf of a putative class of stockholders of Solventum Corporation (the “Company”), filed a Verified Class Action Complaint (the “Action”) in the Court of Chancery of the State of Delaware (the “Delaware Court”), challenging the validity of certain aspects of the advance notice and stockholder nomination provisions of the By-laws of the Company. On September 20, 2024, the Company modified the challenged provisions by…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 21, 2026, the Talent Committee (the “Committee”) of the Board of Directors of Solventum Corporation (the “Company”) adopted and approved the Solventum Executive Severance Plan and Summary Plan Description (the “Severance Plan”), effective June 1, 2026. The Severance Plan provides severance payments and benefits to certain eligible employees…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Wayde McMillan Wayde McMillan Executive Vice President and Chief Financial Officer (Principal Financial Officer) Dated: May 5, 2026
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On March 20, 2026, Mary Wilcox informed Solventum Corporation (the “Company”) of her intent to retire and resign from her position as Chief Accounting Officer of the Company following a search for and appointment of her successor.
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: February 26, 2026
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: November 6, 2025
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 21, 2025, Solventum Corporation (the “Company”) announced that Heather Knight has been appointed to serve in the newly created role of Chief Commercial Officer of the Company, effective as of November 10, 2025. Ms. Knight will oversee all global commercial and R&D operations across the Company’s MedSurg, Dental Solutions and Health Infor…
Completion of Acquisition or Disposition of Assets. On February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement, pursuant to which Buyer agreed to acquire from Solventum certain assets and liabilities related to Solventum’s purification and filtration business. On June 25, 2025, Solventum and Buyer entered into an Amended and Restated Transaction Agreement (the “Agre…
Other Events. On August 22, 2025, Solventum Corporation (the “Company”) issued a press release announcing the commencement of cash tender offers (the “Tender Offers”) to purchase the Company’s outstanding notes of the series listed below for up to $1,750,000,000 aggregate purchase price. The Company is offering to purchase (i) its 5.450% Senior Notes due 2027 (the “2027 Notes”), 5.400% Senior Notes due 2029, 5.600% Senior Notes due 2034 and 5.450% Senior Notes due 2031 for an aggregate purcha…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: August 7, 2025
Entry into a Material Definitive Agreement. As previously disclosed, on February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement (the “Initial Agreement”), pursuant to which, subject to the satisfaction or waiver of certain conditions, Buyer agreed to acquire from Solventum certain assets and liabilities related to Solventum’s purification and filtration business. On…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: May 8, 2025
Entry Into A Material Definitive Agreement. On February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement (the “Agreement”). The Agreement provides that, subject to the satisfaction or waiver of certain conditions, Buyer will acquire from Solventum certain assets and the equity interests of certain entities constituting Solventum’s purification and filtration business…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: February 27, 2025
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: November 7, 2024
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 30, 2024, the Talent Committee of the Board of Directors (the “Committee”) of Solventum Corporation (“Solventum”) approved and adopted the Solventum Executive Change in Control Severance Plan (the “CIC Severance Plan”), which is effective as of such date. Solventum’s Chief Executive Officer (“CEO”), Chief Financial Officer, Chief Account…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: August 8, 2024
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 13, 2024, the Talent Committee (the “Committee”) of the Board of Directors of Solventum Corporation (the “Company”), in connection with the award of restricted stock units (“RSUs”) and performance shares (“PSUs”) to certain executive officers and directors of the Company, approved new forms of restricted stock unit award agreements (the “RSU…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: May 9, 2024
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On April 12, 2024, the Board of Directors (the “Board”) of Solventum Corporation (the “Company”) elected Shirley A. Edwards to the Company’s Board, effective April 12, 2024. Ms. Edwards was a Partner at EY (formerly Ernst & Young LLP) from 2002 to 2022, most recently serving as a Global Client Service Partner from 2017 to 2022. Ms. Edwards will join…
Entry into a Material Definitive Agreement. Separation-Related Agreements On March 31, 2024, Solventum Corporation (“Solventum”) entered into several agreements with 3M Company (“3M”) in connection with the spin-off of 3M’s health care business (the “Separation”) through the pro rata distribution of 80.1% of the issued and outstanding shares of common stock, par value $0.01 per share, of Solventum to 3M’s stockholders of record as of the close of business on March 18, 2024 (the “Distribution”…
Material Modifications to Rights of Security Holders The information set forth under
The biographical information for each other executive officer is set forth below. Mary Wilcox, 60, is the Senior Vice President, Controller and Chief Accounting Officer of Solventum. She joined 3M’s healthcare business in December 2023. Prior to joining Solventum, Ms. Wilcox was Vice President, Chief Accounting Officer at Medtronic PLC (“Medtronic”), a healthcare technology company, where she worked for over 30 years in various roles of increasing responsibility. She also served as Assistant…
Regulation FD Disclosure Information Statement Solventum Corporation (“Solventum”), a wholly owned subsidiary of 3M Company (“3M”), previously filed with the U.S. Securities and Exchange Commission a registration statement on Form 10 (as amended, the “Registration Statement”) relating to the planned distribution by 3M of 80.1% of the issued and outstanding shares of common stock, par value $0.01 per share, of Solventum (the “Solventum common stock”) to 3M shareholders. On March 13, 2024, the…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.